These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 3842104)

  • 21. Factors influencing serum aluminum in CAPD patients.
    Montenegro J; Aguirre R; Saracho R; Moina I; Martínez I
    Clin Nephrol; 1998 Aug; 50(2):77-83. PubMed ID: 9725777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aluminum and chronic renal failure: sources, absorption, transport, and toxicity.
    Wills MR; Savory J
    Crit Rev Clin Lab Sci; 1989; 27(1):59-107. PubMed ID: 2647415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients.
    Kausz AT; Antonsen JE; Hercz G; Pei Y; Weiss NS; Emerson S; Sherrard DJ
    Am J Kidney Dis; 1999 Oct; 34(4):688-93. PubMed ID: 10516350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Water purification in dialysis treatment. Aluminum and encephalopathy].
    Hagstam KE; Lindergård B; Lindholm T; Thysell H
    Lakartidningen; 1980 Jun; 77(26-27):2425-7. PubMed ID: 7401791
    [No Abstract]   [Full Text] [Related]  

  • 25. Occult hypoglycemia caused by hemodialysis.
    Jackson MA; Holland MR; Nicholas J; Talbot M; Spencer H; Lodwick R; Fuhrmann C; Forster D; Macdonald IA
    Clin Nephrol; 1999 Apr; 51(4):242-7. PubMed ID: 10230557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aluminium load in patients with analgesic nephropathy.
    Schwarz A; Kraft D; Keller F; Gawlik D; Offermann G
    Miner Electrolyte Metab; 1987; 13(3):141-6. PubMed ID: 3627045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aluminum in the joint tissues of chronic renal failure patients treated with regular hemodialysis and aluminum compounds.
    Netter P; Kessler M; Burnel D; Hutin MF; Delones S; Benoit J; Gaucher A
    J Rheumatol; 1984 Feb; 11(1):66-70. PubMed ID: 6699835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silicon and aluminium interactions in haemodialysis patients.
    Parry R; Plowman D; Delves HT; Roberts NB; Birchall JD; Bellia JP; Davenport A; Ahmad R; Fahal I; Altmann P
    Nephrol Dial Transplant; 1998 Jul; 13(7):1759-62. PubMed ID: 9681724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide].
    Tahiri Y; Moriniere P; Jaudon MC; Dkhissi H; Rosa A; Fournier A
    Nephrologie; 1983; 4(3):129-33. PubMed ID: 6633778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aluminum distribution in serum following hemodialysis.
    King SW; Savory J; Wills MR
    Ann Clin Lab Sci; 1982; 12(2):143-9. PubMed ID: 7073239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perceived aluminum-related disease in a dialysis population. A report from the End-Stage Renal Disease Network 28.
    Brem AS; DiMario C; Levy DL
    Arch Intern Med; 1989 Nov; 149(11):2541-4. PubMed ID: 2818112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients.
    Canavese C; Petrarulo M; Massarenti P; Berutti S; Fenoglio R; Pauletto D; Lanfranco G; Bergamo D; Sandri L; Marangella M
    Am J Kidney Dis; 2005 Mar; 45(3):540-9. PubMed ID: 15754276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of ion exchange to remove aluminum from water used in hemodialysis.
    Petrie JJ; Fleming R; McKinnon P; Winney RJ; Cowie J
    Am J Kidney Dis; 1984 Jul; 4(1):69-74. PubMed ID: 6741939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
    Nakazawa R
    Clin Calcium; 2004 May; 14(5):738-43. PubMed ID: 15577035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scalp hair as an indicator of aluminium exposure: comparison to bone and plasma.
    Wilhelm M; Passlick J; Busch T; Szydlik M; Ohnesorge FK
    Hum Toxicol; 1989 Jan; 8(1):5-9. PubMed ID: 2785480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dialysis encephalopathy associated with polyvalent ion contamination.
    Hocken AG
    N Z Med J; 1984 Mar; 97(752):190-2. PubMed ID: 6583579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bullous dermatosis of end-stage renal disease: a possible association between abnormal porphyrin metabolism and aluminium.
    Gafter U; Mamet R; Korzets A; Malachi T; Schoenfeld N
    Nephrol Dial Transplant; 1996 Sep; 11(9):1787-91. PubMed ID: 8918623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperaluminemia in renal failure: the influence of age and citrate intake.
    Bakir AA; Hryhorczuk DO; Ahmed S; Hessl SM; Levy PS; Spengler R; Dunea G
    Clin Nephrol; 1989 Jan; 31(1):40-4. PubMed ID: 2914409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.